Oligonucleotide aptamers are short, synthetic, single-stranded DNA or RNA able to recognize and bind to a multitude of targets ranging from small molecules to cells. Aptamers have emerged as valuable tools for fundamental research, clinical diagnosis, and therapy. Due to their small size, strong target affinity, lack of immunogenicity, and ease of chemical modification, aptamers are an attractive alternative to other molecular recognition elements, such as antibodies. Although it is a challenging environment, the central nervous system and related molecular targets present an exciting potential area for aptamer research. Aptamers hold promise for targeted drug delivery, diagnostics, and therapeutics. Here we review recent advances in aptamer research for neurotransmitter and neurotoxin targets, demyelinating disease and spinal cord injury, cerebrovascular disorders, pathologies related to protein aggregation (Alzheimer's, Parkinson's, and prions), brain cancer (glioblastomas and gliomas), and regulation of receptor function. Challenges and limitations posed by the blood brain barrier are described. Future perspectives for the application of aptamers to the central nervous system are also discussed.
Get full access to this article
View all access options for this article.
References
1.
McKeagueM and DeRosa.MC (2012). Challenges and opportunities for small molecule aptamer development. J Nucleic Acids, 2012:748913.
2.
YeM, HuJ, PengM, LiuJ, LiuJ, LiuH, ZhaoX and TanW. (2012). Generating aptamers by cell-SELEX for applications in molecular medicine. Int J Mol Sci, 13:3341–3353.
3.
Cruz-ToledoJ, McKeagueM, ZhangX, GiamberardinoA, McConnellE, FrancisT, DeRosaMC and Dumontier.M (2012). Aptamer base: a collaborative knowledge base to describe aptamers and SELEX experiments. Database (Oxford), 2012:bas006.
4.
TuerkC and GoldL. (1990). Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science, 249:505–510.
5.
EllingtonAD and SzostakJW. (1990). In vitro selection of RNA molecules that bind specific ligands. Nature, 346:818–822.
6.
RobertsonDL and JoyceGF. (1990). Selection in vitro of an RNA enzyme that specifically cleaves single-stranded DNA. Nature, 344:467–468.
7.
JingM and BowserMT. (2011). Methods for measuring aptamer-protein equilibria: a review. Anal Chim Acta, 686:9–18.
8.
BrunoJG. (2013). A review of therapeutic aptamer conjugates with emphasis on new approaches. Pharmaceuticals (Basel), 6:340–357.
9.
WangT and RayJ. (2012). Aptamer-based molecular imaging. Protein Cell, 3:739–754.
10.
LeeJH, YigitMV, MazumdarD and LuY. (2010). Molecular diagnostics and drug delivery agents based on aptamer-nanomaterial conjugates. Adv Drug Deliv Rev, 62: 592–605.
11.
BunkaDHJ, PlatonovaO and StockleyPG. (2010). Development of aptamer therapeutics. Curr Opin Pharmacol, 10:557–562.
12.
TolleF and MayerG. (2013). Dressed for success—applying chemistry to modulate aptamer functionality. Chem Sci, 4:60–67.
13.
YangY, RenX, SchluesenerHJ and ZhangZ. (2011). Aptamers: selection, modification and application to nervous system diseases. Curr Med Chem., 18:4159–4168
14.
AdlerA, ForsterN, HomannM and GöringerHU. (2008). Post-SELEX chemical optimization of a trypanosome-specific RNA aptamer. Comb Chem High T Scr, 11:16–23.
15.
HickeBJ, StephensAW, GouldT, ChangY, LynottCK, HeilJ, BorkowskiS, HilgerC, CookG, WarrenS and SchmidtPG. (2006). Tumor targeting by an aptamer. J Nucl Med, 47:668–678.
16.
ChengC, ChenYH, LennoxKA, BehlkeMA and DavidsonBL. (2013). In vivo SELEX for identification of brain-penetrating aptamers. Mol Ther Nucleic Acids, 2:e67.
17.
de LangeEC.(2013). The mastermind approach to CNS drug therapy: translational prediction of human brain distribution, target site kinetics and therapeutic effects. Fluids Barriers CNS, 10:12
18.
HealyJM, LewisSD, KurzM, BoomerRM, ThompsonKM, WilsonC, McCauleyTG. (2004). Pharmacokinetics and biodistribution of novel aptamer compositions. Pharm Res, 21:2234–2246.
19.
AlyautdinR, KhalinI, NafeezaMI, HaronMH, KuznetsovD. (2014). Nanoscale drug delivery systems and the blood–brain barrier. Int J Nanomedicine, 9:795–811.
20.
HwangSR and KimK. (2014). Nano-enabled delivery systems across the blood–brain barrier. Arch Pharm Res, 37:24–30.
21.
KaeserPS and RegehrWG. (2014). Molecular mechanisms for synchronous, asynchronous, and spontaneous neurotransmitter release. Annu Rev Physiol, 76:333–363.
22.
BisagliaM, FilogranaR, BeltraminiM and BubaccoL. (2014). Are dopamine derivatives implicated in the pathogenesis of Parkinson's disease. Ageing Res Rev, 13:107–114.
23.
AbrahamAD, NeveKA and LattalM. (2014). Dopamine and extinction: A convergence of theory with fear and reward circuitry. Neurobiol Learn Mem, 108:65–77.
24.
SeemanMV and SeemanP. (2014). Is schizophrenia a dopamine supersensitivity psychotic reaction?. Prog Neuropsychopharmacol Biol Psychiatry, 48:155–160.
25.
TrifilieffP and MartinezD. (2014). Imaging addiction: D2 receptors and dopamine signaling in the striatum as biomarkers for impulsivity. Neuropharmacology, 76:498–509.
26.
AndréVM, CepedaC and LevineMS. (2010). Dopamine and glutamate in Huntington's disease: a balancing act. CNS Neurosci Ther, 16:163–178.
27.
BuseJ, SchoenefeldK, MünchauA and RoessnerV. (2013). Neuromodulation in tourette syndrome: dopamine and beyond. Neurosci Biobehav Rev, 37:1069–1084.
28.
VaughanRA and FosterJD. (2013). Mechanisms of dopamine transporter regulation in normal and disease states. Trends Pharmacol Sci, 34:489–496.
29.
MannironiC, Di NardoA, FruscoloniP and Tocchini-ValentiniGP. (1997). In vitro selection of dopamine RNA ligands. Biochemistry, 36:9726–9734.
30.
WalshR and DeRosaMC. (2009). Retention of function in the DNA homolog of the RNA dopamine aptamer. Biochem Biophys Res Commun, 388:732–735.
31.
ZhengY, WangY and YangX. (2011). Aptamer-based colorimetric biosensing of dopamine using unmodified gold nanoparticles. Sens Actuators B Chem, 156:95–99.
32.
ParkH and PaengIR. (2011). Development of direct competitive enzyme-linked aptamer assay for determination of dopamine in serum. Anal Chim Acta, 685:65–73.
33.
KimE and PaengIN. (2014). Advantageous sensitivity in the DNA homolog of the RNA dopamine aptamer. J Immunoassay Immunochem, 35:83–100.
34.
LiuS, XingX, YuJ, LianW, LiJ, CuiM and HuangJ. (2012). A novel label-free electrochemical aptasensor based on grapheme-polyaniline composite film for dopamine determination. Biosens Bioelectron, 36:186–191.
35.
FarjamiE, CamposR, NielsenJS, GothelfKV, KjemsJ and FerapontovaEE. (2013). RNA aptamer-based electrochemical biosensor for selective and label-free analysis of dopamine. Anal Chem, 85:121–128.
36.
JiaoL, LuG, ZhangC, YuanY, WangJ, ZhangQ and LiP. (2013). Aptamer and graphene-based electrochemical biosensor for dopamine determination with high sensitivity and selectivity. Micro Nano Lett, 8:903–905.
37.
LiBR, HsiehYJ, ChenYX, ChungYT, PanCY and ChenYT. (2013). An ultrasensitive nanowire-transistor biosensor for detecting dopamine release from living PC12 cells under hypoxic stimulation. J Am Chem Soc, 135:16034–16037.
38.
HolahanMR, ClarkeMJ and HinesDD. (2010). Dopamine-mediated mk-801-induced elevation in food-based extinction responding in rats and associated changes in region-specific phosphorylated ERK. Psychopharmacology (Berl), 212:393–403.
39.
HolahanMR, MadularuD, McConnellEM, WalshR and DeRosa.MC (2011). Intra-accumbens injection of a dopamine aptamer abates mk-801-induced cognitive dysfunction in a model of schizophrenia. PLoS One, 6:e22239.
40.
BrunoJG, CarrilloMP, PhillipsT and KingB. (2008). Development of DNA aptamers for cytochemical detection of acetylcholine. In Vitro Cell Dev Biol Anim, 44:63–72.
41.
HuizengaDE and SzostakJW. (1995). A DNA aptamer that binds adenosine and ATP Biochemistry, 34:656–665.
42.
ChenSJ, HuangYF, HuangCC, LeeKH, LinZH and ChangHT. (2008). Colorimetric determination of urinary adenosine using aptamer-modified gold nanoparticles. Biosens Bioelectron, 23:1749–1753.
43.
WangJ, ZhangP, LiJY, ChenLQ, HuangCZ and LiYF. (2010). Adenosine-aptamer recognition-induced assembly of gold nanorods and a highly sensitive plasmon resonance coupling assay of adenosine in the brain of model SD rat. Analyst, 135:2826–2831.
44.
BrunoJG, RicharteA and PhillipsT. (2014). Preliminary development of a DNA aptamer-magnetic bead capture electrochemiluminescence sandwich assay for brain natriuretic peptide. Microchem J, 115:32–38.
45.
ZhuJ, WangJ, SuZC, LiQ, ChengMS and ZhangJH. (2008). Identification of ssDNA aptamers specific for anti-neuroexcitation peptide iii and molecular modeling studies: insights into structural interactions. Arch Pharm Res, 31:1120–1128.
46.
MendonsaSD and BowserMT. (2005). In vitro selection of aptamers with affinity for neuropeptide Y using capillary electrophoresis. J Am Chem Soc, 127:9382–9383.
47.
TokunagaT, NamikiS, YamadaK, ImaishiT, NonakaH, HiroseK and SandoS. (2012). Cell surface-anchored fluorescent aptamer sensor enables imaging of chemical transmitter dynamics. J Am Chem Soc, 134:9561–9564.
48.
HandySM, YakesBJ, DeGrasseJA, CampbellK, ElliottCT, KanyuckKM and DegrasseSL. (2012). First report of the use of sazitoxin-protein conjugate to develop a DNA aptamer to a small molecule toxin. Toxicon, 61:30–37.
49.
ČapekP and DickersonTJ. (2010). Sensing the deadliest toxin: technologies for botulinum neurotoxin detection. Toxins (Basel), 2:24–53.
50.
TokJB and FischerNO. (2008). Single microbead SELEX for efficient ssDNA aptamer generation against botulinum neurotoxin. Chem Commun (Camb), 16:1883–1885.
51.
FanM, McBurnettSR, AndrewsCJ, AllmanAM, BrunoJG and KielJL. (2008). Aptamer selection express: a novel method for rapid single-step selection and sensing of aptamers. J Biomol Tech, 19:311–321.
52.
ChangTW, BlankM, JanardhananP, SinghBR, MelloC, BlindM and CaiS. (2010). In vitro selection of RNA aptamers that inhibit the activity of type A botulinum neurotoxin. Biochem Biophys Res Commun, 396:854–860.
53.
BrunoJG, RicharteAM, CarrilloMP and EdgeA. (2012). An aptamer beacon responsive to botulinum toxins. Biosens Bioelectron, 31:240–243.
54.
WeiF and HoCM. (2009). Aptamer-based electrochemical biosensor for Botulinum neurotoxin. Anal Bioanal Chem, 393:1943–1948.
55.
WeiF, BaiB and HoCM. (2011). Rapidly optimizing an aptamer based BoNT sensor by feedback system control (FSC) scheme. Biosens Bioelectron, 30:174–179.
56.
JanardhananP, MelloCM, SinghBR, LouJ, MarksJD and CaiS. (2013). RNA aptasensor for the rapid detection of natively folded type A botulinum neurotoxin. Talanta, 117:273–280.
57.
NastasijevicB, WrightBR, SmestadJ, WarringtonAE, RodriguezM and Maher.LJM (2012) Remyelination induced by a DNA aptamer in a mouse model of multiple sclerosis. PLOS One, 7: e39595
VorobjevaMA, KrasitskayaVV, FokinaAA, TimoshenkoVV, NevinskyGA, VenyaminovaAG and FrankLA. (2014). RNA aptamer against autoantibodies associated with multiple sclerosis and bioluminescent detection probe on its basis. Anal Chem, 86:2590–2594.
60.
TylerJY, XuXM and ChengJX. (2013) Nanomedicine for treating spinal cord injury. Nanoscale, 5:8821–8836.
61.
WangY, KhaingZZ, LiN, HallB, SchmidtCE and Ellington.AD (2010). Aptamer antagonists of myelin-derived inhibitors promote axon growth. PLOS One, 5:e9726
62.
KalladkaD and MuirKW. (2014). Brain repair: cell therapy in stroke. Stem Cells Cloning, 7:31–44.
63.
BlakeCM, WangH, LaskowitzDT and SullengerBA. (2011). A reversible aptamer improves outcome and safety in murine models of stroke and hemorrhage. Oligonucleotides., 21:11–19.
64.
MayerG, RohrbachF, PötzschB and MüllerJ. (2011). Aptamer-based modulation of blood coagulation. Hämostaseologie, 4:258–263.
65.
RusconiCP, ScardinoE, LayzerJ, PitocGA, OrtelTL, MonroeD and SullengerBA. (2002). RNA aptamers as reversible antagonists of coagulation factor IXa. Nature, 419:90–94.
66.
DienerJL, LagasséHAD, DuerschmiedD, MerkiY, TanguyJF, HutabaratR, GilbertJ, WagnerDD and SchaubR. (2009). Inhibition of von Willebrand factor-mediated platelet activation and thrombosis by the anti-von Willebrand factor A1-domain aptamer ARC1779. J Thromb Haemost, 7:1155–1162.
67.
BaeON. (2012). Targeting von Willebrand Factor as a novel anti-platelet therapy; application of ARC1779, an anti-vWF aptamer, against thrombotic risk. Arch Pharm Res, 35:1693–1699.
68.
MarkusHS, McCollumC, ImrayC, GoulderMA, GilbertJ and KingA. (2011). The von Willebrand inhibitor ARC1779 reduces cerebral embolization after carotid endarterectomy a randomized trial. Stroke, 42:2149–2153.
69.
DenekasT, TröltzschM, VaterA, KlussmannS and MesslingerK. (2006). Inhibition of stimulated meningeal blood flow by a calcitonin gene-related peptide binding mirror-image RNA oligonucleotide. Br J Pharmacol, 148:536–543.
70.
VaterA, JaroschF, BuchnerK and Klussmann.S (2003). Short bioactive Spiegelmers to migraine-associated calcitonin gene-related peptide rapidly identified by a novel approach: tailored-SELEX. Nucleic Acids Res, 31:e130.
71.
AmiriH, SaeidiK, BorhaniP, ManafiradA, GhavamiM and ZerbiV. (2013). Alzheimer's disease: pathophysiology and applications of magnetic nanoparticles as mri theranostic agents. ACS Chem Neurosci, 4:1417–1429.
72.
TannenbergRK, ShamailehHA, LauridsenLH, KanwarJR, DoddPR and VeeduRN. (2013). Nucleic acid aptamers as novel class of therapeutics to mitigate Alzheimer's disease pathology. Curr Alzheimer Res, 10:442–448.
73.
RahimiF, MurakamiK, SummersJL, ChenCH, and Bitan.G (2009). RNA aptamers generated against oligomeric Aβ40 recognize common amyloid aptatopes with low specificiy but high sensitivity. PLoS ONE, 4:e7694.
74.
YleraF, LurzR, ErdmannVA and FϋrsteJP. (2002). Selection of RNA aptamers to the alzehimer's disease amyloid peptide. Biochem Biophys Res Commun, 290:1583–1588.
75.
TakahashiT, TadaK and MiharaH. (2009). RNA aptamers selected against amyloid β-peptide (Aβ) inhibit the aggregation of Aβ. Mol Biosyst, 5:986–991.
76.
MathewA, AravindA, BrahatheeswaranD, FukudaT, NagaokaY, HasumuraT, IwaiS, MorimototH, YoshidaY, et al. (2012). Amyloid-binding aptamer conjugated curcumin-plga nanoparticle for potential use in Alzheimer's disease. BioNanoSci, 2:83–93.
77.
BunkaDHJ, MantleBJ, MortenIJ, TennentGA, RadfordSE and StockleyPG (2007). Production and characterization of RNA aptamers specific for amyloid fibril epitopes. J Biol Chem, 282:34500–34509.
78.
RentmeisterA, BillA, WahleT, WalterJ and FamulokM. (2006). RNA aptamers selectively modulate protein recruitment to the cytoplasmic domain of β-secretase BACE1 in vitro. RNA, 12:1650–1660.
79.
OzawaD, NakamuraT, KoikeM, HiranoK, MikiY and BeppuM. (2013). Shuttling protein nucleolin is a microglia receptor for amyloid beta peptide 1–42. Biol Pharm Bull, 36:1587–1593.
80.
IresonCR and KellandLR. (2006). Discovery and development of anticancer aptamers. Mol Cancer Ther, 5:2957–2962.
81.
LolloB, SteeleF and GoldL. (2014). Beyond antibodies: New affinity reagents to unlock the proteome. Proteomics, 14:638–644.
82.
KiddleSJ, SattleckerM, ProitsiP, SimmonsA, WestmanE, BazenetC, NelsonSK, WilliamsS, HodgesA, JohnstonC, SoininenH, KloszewskaI, MecocciP, TsolakiM, VellasB, NewhouseS, LovestoneS and DobsonRJB. (2014). Alzheimer's disease onset and progression: a systematic review and replication study. J Alzheimers Dis, 38:515–531.
83.
GuptaS, HirotaM, WaughSM, MurakamiI, SuzukiT, MuraguchiM, ShibamoriM, IshikawaY, JarvisTC, et al. (2014) Chemically-modified DNA aptamers bind interleukin-6 with high affinity and inhibit signaling by blocking its interaction with interleukin-6 receptor. J Biol Chem, 289:8706–8719
84.
BairdGS, NelsonSK, KeeneyTR, StewartA, WilliamsS, KraemerS, PeskindER and MontineTJ. (2012) Age-dependent changes in the cerebrospinal fluid proteome by slow-off-rate modified aptamer array. Am J Pathol, 180:446–456.
85.
FarrarCT, WilliamCM, HurdyE, HashimotoT and Hyman.BT (2014). RNA aptamer probes as optical imaging agents for the detection of amyloid plaques. PLoS ONE, 9:e89901.
86.
TsukakoshiK, HaradaR, SodeK and IkebukuroK. (2010). Screening of DNA aptamer which binds to α-synuclein. Biotechnol Lett, 32:643–648.
87.
TsukakoshiK, AbeK, SodeK and IkebukuroK. (2012). Selection of DNA aptamers that recognize α-synuclein oligomers using a competitive screening method. Anal Chem, 84:5542–5547.
88.
AguzziA and FalsigJ. (2012). Prion propagation, toxicity and degradation. Nat Neurosci, 15:936–939.
89.
BoeseAS, MajerA, SabaR and BoothSA. (2013). Small RNA drugs for prion disease: a new frontier. Expert Opin Drug Discov, 8:1265–1284.
90.
GilchS and SchätzlHM. (2009). Aptamers against prion proteins and prions. Cell Mol Life Sci, 66:2445–2455.
91.
PraseethaPK, AnandST, VenugopalanP and MurthySC. (2012). Molecular nanobiotechnological approaches for the detection and therapy of prion related diseases. Nano Biomed Eng, 4:50–57.
92.
YangY, YangD, SchluesenerHJ and ZhangZ. (2007). Advances in SELEX and application of aptamers in the central nervous system. Biomol Eng, 24:583–592.
93.
OgasawaraD, HasegawaH, KanekoK, SodeK and IkebukuroK. (2007). Screening of DNA aptamer against mouse prion protein by competitive selection. Prion, 1:248–254.
94.
MurakamiK, NishikawaF, NodaK, YokoyamaT and NishikawaS. (2008). Anti-bovine prion protein RNA aptamer containing tandem GGA repeat interacts both with recombinant bovine prion protein and its β isoform with high affinity. Prion, 2:73–80.
95.
MashimaT, MatsugamiA, NishikawaF, NishikawaS and KatahiraM. (2009). Unique quadruplex structure and interaction of an RNA aptamer against bovine prion protein. Nucleic Acids Res, 37:6249–6258.
96.
BibbyDF, GillAC, KirbyL, FarquharCF, BruceME and GarsonJA. (2008). Application of a novel in vitro selection technique to isolate and characterize high affinity DNA aptamers binding mammalian prion proteins. J Virol Methods, 151:107–115.
97.
RhieA, KirbyL, SayerN, WellesleyR, DistererP, SylvesterI, GillA, HopeJ, JamesW and Tahiri-AlaouiA. (2003). Characterization of 2′-fluoro-RNA aptamers that bind preferentially to disease-associated conformations of prion protein and inhibit conversion. J Biol Chem, 278:39697–39705.
98.
TakemuraK, WangP, VorbergI, SurewiczW, PriolaSA, KanthasamyA, PottathilR, ChenSG and SreevatsanS. (2006). DNA aptamers that bind to PrP(C) and not PrP(Sc) show sequence and structure specificity. Exp Biol Med (Maywood), 231:204–214.
99.
SayerN.M., CubinM., RhieA., BullockM., Tahiri-AlaouiA., and JamesW. (2004). Structural determinants of conformationally selective, prion-binding aptamers. J Biol Chem, 279:13102–13109.
100.
KouassiGK, WangP, SreevatanS and IrudayarajJ. (2007). Aptamer-mediated magnetic nanoparticles as detection assay for prion protein assessment. Biotechnol Prog, 23:1239–1244.
101.
XiaoSJ, HuPP, LiYF, HuangCZ, HuangT and XiaoGF. (2009). Aptamer-mediated turn-on fluorescence assay for prion protein based on guanine quenched fluophor. Talanta, 79:1283–1286.
102.
HossainMT, ShibataT, KabashimaT and KaiM. (2010). Aptamer-Mediated Chemiluminescence Detection of Prion Protein on Membrane using Trimethoxyphenylglyoxal. Anal Sci, 26:645–647.
103.
XiaoSJ, HuPP, WuXD, ZouYL, ChenLQ, PengL, LingJ, ZhenSJ, ZhanL, LiYF and HuangCZ. (2010). Sensitive discrimination and detection of prion disease-associated isoform with a dual-aptamer strategy by developing a sandwich structure of magnetic microparticles and quantum dots. Anal Chem, 82:9736–9742.
104.
XiaoSJ, HuPP, XiaoGF, WangY, LiuY and HuangCZ. (2012). Label-free detection of prion protein with its DNA aptamer through the formation of T-Hg2+−T configuration. J Phys Chem B, 116:9565–9569.
105.
ZhanL, PengL, YuY, ZhenSJ and HuangCZ. (2012). Sensitive spectrofluorometry of cellular prion protein based on the on-off interaction between fluorescent dye-labelled aptamers and multi-walled carbon nanotubes. Analyst, 137:4968–4973.
106.
HuPP, ZhengLL, ZhanL, LiJY, ZhenSJ, LiuH, LuoLF, XiaoGF and HuangCZ. (2013). Metal-enhanced fluorescence of nano-core-shell structure used for sensitive detection of prion protein with a dual-aptamer strategy. Anal Chim Acta, 787:239–245.
107.
MiodekA, PoturnayováA, M Šnejdárková, HianikT and Korri-YoussoufiH. (2013). Binding kinetics of human cellular prion detection by DNA aptamers immobilized on a conducting polypyrrole. Anal Bioanal Chem, 405:2505–2514.
108.
MiodekA, CastilloG, HianikT and Korri-YoussoufiH. (2013). Electrochemical aptasensor of human cellular prion based on multiwalled carbon nanotubes modified with dendrimers: a platform for connecting redox markers and aptamers. Anal Chem, 85:7704–7712.
109.
XiaoSJ, HuPP, ChenLQ, ZhenSJ, PengL, LiYF and HUANG.Z (2013). A visual dual-aptamer logic gate for sensitive discrimination of prion diseases-associated isoform with reusable magnetic microparticles and fluorescence quantum dots. PLoS ONE, 8:e53935.
110.
ZhanL, LiangLJ, ZhenSJ, LiCM and HuangCZ. (2013). Aptamer-based spectrofluorometry for cellular prion protein using N,N′-bis[3,3′-(dimethylamino)propylamine]-3,4,9,10-perylenetetracarboxylic diimide. Analyst, 138:825–830.
111.
ZhenSJ, ZhuangHL, WangJ and HuangCZ. (2013). Dual-aptamer-based sensitive and selective detection of prion protein through the fluorescence resonance energy transfer between quantum dots and grapheme oxide. Anal Methods, 5:6904–6907.
112.
ZhouYW, LiCM, LiuY and HuangCZ. (2013). Effective detection and cell imaging of prion protein with new prepared targetable yellow-emission silver nanoclusters. Analyst, 138:873–878.
113.
ZhuangHL, ZhenSJ, WangJ and HuangCZ. (2013). Sensitive detection of prion protein through long range resonance energy transfer between grapheme oxide and molecular aptamer beacon. Anal Methods, 5:208–212.
114.
MiodekA, CastilloG, HianikT and Korri-YoussoufiH. (2014). Electrochemical aptasensor of cellular prion protein based on modified polypyrrole with redox dendrimers. Biosens Bioelectron, 56:104–111.
115.
ChenLQ, XiaoSJ, HuPP, PengL, MaJ, LuoLF, LiYF and HuangCZ. (2012). Aptamer-mediated nanoparticle-based protein labeling platform for intracellular imaging and tracking endocytosis dynamics. Anal Chem, 84:3099–3110.
116.
MashimaT, NishkawaF, KamatariYO, FujiwaraH, SaimuraM, NagataT, KodakiT, NishikawaS, KuwataK and KatahiraM. (2013). Anti-prion activity of an RNA aptamer and its structural basis. Nucleic Acids Res, 41:1355–1362.
117.
BlankM, WeinschenkT, PriemerM and SchluesenerH. (2001). Systemic evolution of dna aptamer binding to rat brain tumor microvessels. Selective targeting of endothelial regulatory protein pigpen. J Biol Chem, 276:16464–16468.
118.
CerchiaL, DucongeF, PestourieC, BoulayJ, AissouniY, GombertK, TavitianB, de FranciscisV and Libri.D (2005). Neutralizing aptamers from whole-cell SELEX inhibit the ret receptor tyrosine kinsase. PLoS Biol, 3:e123.
119.
DanielsDA, ChenH, HickeBJ, SwiderekKM and GoldL. (2003). A tenascin-C aptamer identified by tumor cell SELEX: systemic evolution of ligands by exponential enrichment. Proc Natl Acad Sci USA, 100:15416–15421.
120.
HickeBJ, MarionC, ChangYF, GouldT, LynottCK, ParmaD, SchmidtPG and WarrenS. (2001). Tenascin-C Aptamers are generated using tumor cells and purified protein. J Biol Chem, 276:48644–48654.
121.
de FranciscisV, EspositoCL, CatuognoS, CellaiL and CerchiaL. (2009). Aptamers as innovative diagnostic and therapeutic agents in the central nervous system. CNS Neurol Disord Drug Targets, 8:393–401.
122.
KangD, WangJ, ZhangW, SongY, LiX, ZouY, ZhuM, ZhuZ, ChenF and Yang.CJ (2012). Selection of DNA aptamers against glioblastoma cells with high affinity and specificity. PLoS ONE, 7:e42731.
123.
BayracAT, SefahK, ParekhP, BayracC, GulbakanB, OktemHA and TanW. (2011). In vitro selection of DNA aptamers to glioblastoma multiforme. ACS Chem Neurosci, 2:175–181.
124.
CerchiaL, EspositoCL, JacobsAH, TavitianB and de FranciscisV. (2009). Differential SELEX in human glioma cell lines. PLoS ONE, 4:e7971.
125.
KimY, WuQ, HamerlikP, HitomiM, SloanAE, BarnettGH, WeilRJ, LeahyP, HjelmelandAB and RichJN. (2013). Aptamer identification of brain tumor-initiating cells. Cancer Res, 73:4923–4936.
126.
Da Rocha GomesS, MiguelJ, AzémaL, EimerS, RiesC, DausseE, LoiseauH, AllardM and ToulméJJ. (2012). 99mTc-MAG3-Aptamer for imaging human tumors associated with high level of matrix metalloprotease-9. Bioconjug Chem, 23:2192–2200.
127.
ChengY, MorshedRA, AuffingerB, TobiasAL and LesniakMS. (2014). Multifunctional nanoparticles for brain tumor imaging and therapy. Adv Drug Deliv Rev, 66:42–57.
128.
Hernández-PedroNY, Rangel-LópezE, Magaña-MaldonadoR, de La CruzVP, del AngelAS, PinedaB and Sotelo.J (2013). Application of nanoparticles on diagnosis and therapy in gliomas. Biomed Res Int, 2013:351031.
129.
LiZ, HuangP, HeR, LinJ, YangS, ZhangX, RenQ and CuiD. (2010). Aptamer-conjugated dendrimer-modified quantum dots for cancer cell targeting and imaging. Mater Lett, 64:375–378.
130.
LiJ and ZhuJJ. (2013). Quantum dots for fluorescent biosensing and bio-imaging applications. Analyst, 138:2506–2515.
131.
KimB, YangJ, HwangM, ChoiJ, KimHQ, JangE, LeeJH, RyuSH, SuhJS, HuhYM and HaamS. (2013). Aptamer-modified magnetic nanoprobe for molecular MR imaging of VEGFR2 on angiogenic vasculature. Nanoscale Res Lett, 8:399–409.
132.
NairBG, NagaokaY, MorimotoH, YoshidaY, MaekawaT and Kumar.DS (2010). Aptamer conjugated magnetic nanoparticles as nanosurgeons. Nanotechnology, 21:455102.
133.
LiuY, KuanC, MiJ, ZhangX, ClaryBM, BignerDD and SullengerBA. (2009). Aptamers selected against the unglycosylated EGFRvIII ectodomain and delivered intracellularly reduce membrane-bound EGFRvIII and induce apoptosis. Biol Chem, 390:137–144.
134.
BechetD, MordonSR, GuilleminF and Barberi-HeyobMA. (2012). Photodynamic therapy of malignant brain tumors: a complementary approach to conventional therapies. Cancer Treat Rev, 40:229–241.
HuseJT and HollandEC. (2010). Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer, 10:319–331.
141.
GaoH, QianJ, CaoS, YangZ, PangZ, PanS, FanL, XiZ, JiangX and ZhangQ. (2012). Precise glioma targeting of and penetration by aptamer and peptide dual-functioned nanoparticles. Biomaterials, 33:5115–5123.
142.
LiJ, FengL, FanL, ZhaY, GuoL, ZhangQ, ChenJ, PangZ, WangY, et al. (2011). Targeting the brain with PEG-PLGA nanoparticles modified with phage-displayed peptides. Biomaterials, 32:4943–4950.
PorcianiD, SignoreG, MarchettiL, MereghettiP, NifosiR and Beltram.F (2014). Two interconvertible folds modulate the activity of a DNA aptamer against transferrin receptor. Mol Ther Nucleic Acids, 3:e144.
145.
MuC, DaveN, HuJ, DesaiP, PaulettiG, BaiS and HaoJ. (2013). Solubilization of flurbiprofen into aptamer-modified PEG-PLA micelles for targeted delivery to brain-derived endothelial cells in vitro. J Microencapsul, 30:701–708.
146.
WilnerSE, WengerterB, MaierK, de Lourdes Borba MagalhãesM, Del AmoDS, PaiS, OpazoF, RizzoliSO, YanA and Levy.M (2012). An RNA alternative to human transferrin: a new tool for targeting human cells. Mol Ther Nucleic Acids, 1:e21.
147.
HuangZ, PeiW, JayaseelanS, ShiH and NiuL. (2007). RNA aptamers selected against the GluR2 glutamate receptor channel. Biochemistry, 46:12648–12655.
148.
DuM, UlrichH, ZhaoX, AronowskiJ, JayaramanV. (2007). Water soluble RNA based antagonist of AMPA receptors. Neuropharmacology, 53:242–251.
149.
LiuY, SunQ, ChenQ, LeeTH, HuangY, WetselWC, MichelottiGA, SullengerBA and ZhangX. (2009). Targeting inhibition of GluR1 Ser845 phosphorylation with an RNA aptamer that blocks AMPA receptor trafficking. J Neurochem, 108:147–157.
150.
UlrichH, IppolitoJE, PagánOR, EterovićVA, HannRM, ShiH, LisJT, EldefrawiME and HessG. (1998). In vitro selection of RNA molecules that displace cocaine from the membrane-bound nicotinic acetylcholine receptor. Proc Natl Acad Sci USA, 95:14051–14056.
151.
HessGP, UlrichH, BreitingerH, NiuL, GamerioAM, GrewerC, SrivastavaS, IppolitoJE, LeeSM, JayaramanV and CoombsSE. (2000). Mechanism-based discovery of ligands that counteract inhibition of the nicotinic acetylcholine receptor by cocaine and MK-801. Proc Natl Acad Sci (USA), 97:13895–13900.
152.
SivaprakasamK, PagánOR and HessGP. (2010). Minimal RNA aptamer sequences that can inhibit or alleviate noncompetitive inhibition of muscle-type nicotinic acetylcholine receptor. J Membr Biol, 233:1–12.
153.
CuiY, UlrichH and HessGP. (2004). Selection of 2′-fluoro-modified RNA aptamers for alleviation of cocaine and mk-801 inhibition of the nicotinic acetylcholine receptor. J Membr Biol, 202:137–149.
154.
KrivosheinAV and HessGP. (2004). Mechanism-based approach to the successful prevention of cocaine inhibition of the neuronal (α3β4) nicotinic acetylcholine receptor. Biochemistry, 43:481–489.
155.
CuiY, RajaesthupathyP and HessGP. (2004). Selection of stable RNA molecules that can regulate the channel-opening equilibrium of the membrane-bound γ-aminobutyric acid receptor. Biochemistry, 43:16442–16449.
156.
HuangYZ, HernandezFJ, GuB, StockdaleKR, NanapaneniK, ScheetzTE, BehlkeMA, PeekAS, BairT, GiangrandePH and McNamaraJO. (2012). RNA aptamer-based functional ligands of the neurotrophin receptor, TrkB. Mol Pharmacol, 82:623–635.
157.
GaoX and LiC. (2014). Nanoprobes visualizing gliomas by crossing the blood brain tumor barrier. Small, 10:426–440.
158.
BertelsonJA and AjtaiB. (2014). Neuroimaging of dementia. Neurol Clin, 32:59–93.
159.
ScheckAC and StaffordP. (2012). Design and use of biomarkers for the current and future clinical management of brain tumors. Biomark Med, 6:293–295.
160.
El-JawahriA, PatelD, ZhangM, MladkovaN and ChakravartiA. (2008). Biomarkers of clinical responsiveness in brain tumor patients: progress and potential. Mol Diagn Ther, 12:199–208.
161.
MarciniukK, TaschukR and Napper.S (2013). Evidence for prion-like mechanisms in several neurodegenerative diseases: potential implications for immunotherapy. Clin Dev Immunol, 2013:473706.
162.
BerezovskiMV, LechmannM, MusheevMU, MakTW and KrylovSN. (2008). Aptamer-facilitated biomarker discovery (AptaBiD). J Am Chem Soc, 130:9137–9143.
163.
SchaefferE and DuplantierA. (2010) Glutamate and neurodegenerative disease. Top Med Chem, 6:91–147.
164.
BradyROJr, McCarthyJM, PrescotAP, JensenJE, CopperAJ, CohenBM, Renshaw and D ÖngürPF. (2013) Brain gamma-aminobutyric acid (GABA) abnormalities in bipolar disorder. Bipolar Disord, 15:434–439.
165.
MurphyDL, MoyaPR, FoxMA, RubensteinLM, WendlandJR and Timpano.KR (2013) Anxiety and affective disorder comorbidity related to serotonin and other neurotransmitter systems: obsessive–compulsive disorder as an example of overlapping clinical and genetic heterogeneity. Philos Trans R Soc Lond B Biol Sci, 368:20120435.
